PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Status
- RECRUITING
- Phase
- PHASE1
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
- Status
- RECRUITING
- Phase
- PHASE2
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- Status
- SUSPENDED
- Phase
- PHASE1
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
- Status
- RECRUITING
- Phase
- PHASE1
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE3
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient
- Status
- UNKNOWN
- Phase
- NA
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1